Literature DB >> 21860085

Regional comparison of the neurogenic effects of CNTF-derived peptides and cerebrolysin in AβPP transgenic mice.

Edward Rockenstein1, Kiren Ubhi, Edith Doppler, Philipp Novak, Herbert Moessler, Bin Li, Julie Blanchard, Inge Grundke-Iqbal, Khalid Iqbal, Michael Mante, Anthony Adame, Leslie Crews, Eliezer Masliah.   

Abstract

Adult neurogenesis, the production of new neurons in certain brain regions, is known to decrease with age and the loss of neurogenic potential has been implicated in Alzheimer's disease (AD), a leading cause of dementia in the elderly. Cerebrolysin (CBL) has been shown to increase neurogenesis in models of stroke and AD. CBL is composed of small peptides with activity similar to neurotrophic factors including ciliary neurotrophic factor (CNTF), which may mediate its neurogenic effects. This study compares the effects of CBL and two peptides with corresponding to an active region of CNTF (Peptide 6 and 6A) across neurogenic brain regions in amyloid-β protein precursor (AβPP) transgenic (tg) mice. Both CBL and Peptides 6 and 6A were able to increase the numbers of neuroblasts (DCX+ cells) and BrdU+ cells in a regionally specific manner across the subventricular zone, olfactory bulb, and hippocampus. The increased generation of new cells and cell survival in animals treated with Peptides 6 and 6A was accompanied by an increase in PCNA+ cells. In contrast, AβPP tg mice treated with CBL displayed reduced levels of TUNEL staining, while levels of PCNA were unaltered. Collectively these results demonstrate that while CBL and Peptides 6 and 6A all potentiate neurogenesis in the AβPP tg mice, their relative modes of action may differ with CBL associated with reduced apoptosis and Peptides 6 and 6A working by augmenting cell proliferation. These results are consistent with a potential therapeutic relevance for Peptides 6 and 6A in AD and other disorders characterized by neurogenic deficits.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21860085      PMCID: PMC3925781          DOI: 10.3233/JAD-2011-110914

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  33 in total

1.  Inhibitory effect of a brain derived peptide preparation on the Ca++-dependent protease, calpain.

Authors:  R Wronski; P Tompa; B Hutter-Paier; K Crailsheim; P Friedrich; M Windisch
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

2.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

3.  Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide.

Authors:  Muhammad Omar Chohan; Bin Li; Julie Blanchard; Yunn-Chyn Tung; Agnes T Heaney; Ausma Rabe; Khalid Iqbal; Inge Grundke-Iqbal
Journal:  Neurobiol Aging       Date:  2009-09-19       Impact factor: 4.673

4.  Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42).

Authors:  E Rockenstein; M Mallory; M Mante; A Sisk; E Masliaha
Journal:  J Neurosci Res       Date:  2001-11-15       Impact factor: 4.164

Review 5.  Structural correlates of cognition in dementia: quantification and assessment of synapse change.

Authors:  S T DeKosky; S W Scheff; S D Styren
Journal:  Neurodegeneration       Date:  1996-12

Review 6.  Neurotrophic activities and therapeutic experience with a brain derived peptide preparation.

Authors:  M Windisch; A Gschanes; B Hutter-Paier
Journal:  J Neural Transm Suppl       Date:  1998

7.  Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity.

Authors:  S T DeKosky; S W Scheff
Journal:  Ann Neurol       Date:  1990-05       Impact factor: 10.422

8.  Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: evidence for decreased neuronal somal size and increased neuronal density.

Authors:  Gursharan Chana; Sabine Landau; Clare Beasley; Ian P Everall; David Cotter
Journal:  Biol Psychiatry       Date:  2003-06-15       Impact factor: 13.382

9.  The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance.

Authors:  E Rockenstein; A Adame; M Mante; H Moessler; M Windisch; E Masliah
Journal:  J Neural Transm (Vienna)       Date:  2003-11       Impact factor: 3.575

10.  Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease.

Authors:  E M Rockenstein; L McConlogue; H Tan; M Power; E Masliah; L Mucke
Journal:  J Biol Chem       Date:  1995-11-24       Impact factor: 5.157

View more
  4 in total

Review 1.  Peptides Derived from Growth Factors to Treat Alzheimer's Disease.

Authors:  Suzanne Gascon; Jessica Jann; Chloé Langlois-Blais; Mélanie Plourde; Christine Lavoie; Nathalie Faucheux
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

Review 2.  Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease.

Authors:  Syed Faraz Kazim; Khalid Iqbal
Journal:  Mol Neurodegener       Date:  2016-07-11       Impact factor: 14.195

3.  Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-β levels.

Authors:  Anna M Lilja; Jennie Röjdner; Tamanna Mustafiz; Carina M Thomé; Elisa Storelli; Daniel Gonzalez; Christina Unger-Lithner; Nigel H Greig; Agneta Nordberg; Amelia Marutle
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

4.  Neuroprotective effects of sulforaphane on cholinergic neurons in mice with Alzheimer's disease-like lesions.

Authors:  Rui Zhang; Jingzhu Zhang; Lingduo Fang; Xi Li; Yue Zhao; Wanying Shi; Li An
Journal:  Int J Mol Sci       Date:  2014-08-18       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.